Moreno C, Byrd JC, Hillmen P, et al. Ibrutinib in previously treated chronic lymphocytic leukemia updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 2017, abstract S769.
Efanesoctocog alfa als profylaxe bij kinderen met ernstige hemofilie A
nov 2024 | Benigne hematologie